Sign In
Buy LLY
$1,083.23
+18.39 (+1.73%)
At Close: Jun 03, 2026
Novo Nordisk's Wegovy pill maintains strong lead over Eli Lilly rival despite weekly dip, Citi says
08:17am, Monday, 18'th May 2026
Novo Nordisk's (NYSE:NVO) oral version of its blockbuster weight-loss drug Wegovy continues to outpace its main competitor despite a slight weekly decline in prescriptions, according to Citi's late
Could Eli Lilly's Next Weight Loss Drug Waylay Wegovy -- and Even Zap Zepbound?
01:00am, Sunday, 17'th May 2026
After stealing the show with Zepbound, Eli Lilly could further gain an edge in the market with its latest weight loss treatment, retatrutide. In recent clinical trials, the drug has demonstrated that
Lilly, Caitlin Clark Foundation, and Musco Lighting open three community sports courts in Indianapolis, expanding year-round access for youth
Lilly to provide park and court to the City of Indianapolis as part of its 150th anniversary celebration INDIANAPOLIS, May 16, 2026 /PRNewswire/ -- The Caitlin Clark Foundation, in partnership with El
BIIB Advances Alzheimer's Disease Drug Despite Study Missing Main Goal
12:31pm, Friday, 15'th May 2026
Biogen advances Alzheimer's drug diranersen to late-stage trials after a phase II study misses its main goal but shows cognitive and biomarker gains.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
10:00am, Friday, 15'th May 2026
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Is Eli Lilly Going To $1,100?
01:34pm, Thursday, 14'th May 2026
Eli Lilly (NYSE:LLY | LLY Price Prediction) just delivered one of the most impressive quarters in big pharma history, and the stock is responding.
Lilly and UNICEF collaborate to give millions of children a healthier start
07:00am, Thursday, 14'th May 2026
Six-year initiative to improve non-communicable disease prevention and care for children in low- and middle-income countries NEW YORK and INDIANAPOLIS, May 14, 2026 /PRNewswire/ -- Eli Lilly and Compa
Isomorphic Labs' $2.1 Billion Fundraise Is The Biggest Bet Yet On AI Drug Discovery
06:15pm, Wednesday, 13'th May 2026
On Tuesday, Isomorphic Labs, the Alphabet-founded firm that uses AI to accelerate drug development, said that it had raised $2.1 billion from investors led by Thrive Capital. That's a boatload of cash
Charts to Watch: SPX All-Time High, CIFR & LLY Breakouts
03:30pm, Wednesday, 13'th May 2026
@CharlesSchwab's Kevin Horner breaks down key market charts as the S&P 500 (SPX) taps new record highs, backed by investors defending the 10-day SMA. In stock movers, he highlights notable technical s
This Weight-Loss Drug Challenger Could Follow Eli Lilly's Playbook: Analyst
02:43pm, Wednesday, 13'th May 2026
On Tuesday, William Blair initiated coverage on Kailera Therapeutics Inc. (NASDAQ:KLRA), the latest entrant in the fast-growing weight-loss drug market.
Lilly Bets on Next-Generation Obesity Drugs to Stay Ahead
12:52pm, Wednesday, 13'th May 2026
LLY expands beyond tirzepatide with oral obesity pills and next-gen drugs like retatrutide to defend its lead in the booming weight-loss market.
Eli Lilly Says Newly Approved Foundayo, Lower-Dose Zepbound Help Sustain Weight Loss
11:33am, Wednesday, 13'th May 2026
Eli Lilly and Co. (NYSE:LLY) on Wednesday released detailed findings from two late-stage obesity studies showing patients were able to maintain significant weight loss after switching from higher-dose
Eli Lilly launches Alzheimer's drug Donanemab in India
05:28am, Wednesday, 13'th May 2026
U.S.-based drugmaker Eli Lilly on Wednesday launched its Alzheimer's drug Lormalzi, also known as Donanemab, in India.
In ATTAIN-MAINTAIN, participants who transitioned from a maximum tolerated dose (MTD) of Wegovy (semaglutide) to Foundayo maintained all but 0.9 kg of their previously achieved weight loss on average
